|
Accueil > Actualité
Bristol Myers: positive Phase 3 data in NSCLC
(CercleFinance.com) - Bristol Myers Squibb reports positive data from the phase 3 CheckMate-816 study, which evaluated its Opdivo with chemotherapy as neoadjuvant treatment for adults with resectable non-small cell lung cancer (NSCLC).
According to the final analysis, the results showed a statistically and clinically significant improvement in overall survival, a key secondary endpoint, compared to neoadjuvant chemotherapy alone. These results are in addition to the previously reported primary endpoints of event-free survival and pathological complete response, which also achieved statistical significance. No new safety signals were observed. Copyright (c) 2025 CercleFinance.com. All rights reserved. |
21/02/2025 17:32
ADPpoursuit son repli, l'avis d'un analyste 21/02/2025 17:06 Rolls-Roycecontrat d'achat d'électricité avec SWU 21/02/2025 16:41 Airbusle satellite 'Biomass' de l'ESA en route pour Kourou 21/02/2025 16:30 KKRinvestit dans un complexe de logements à Stockholm 21/02/2025 15:45 Engiela Commission européenne approuve une aide d'Etat 21/02/2025 15:35 Repsolplombé par une dégradation de broker Tous les articles sociétés |
